This study indicated that in addition to antiparasitic activity, avermectin analogues are promising drug candidates to treat metabolism syndrome including NAFLD by directly targeting FXR. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.